Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sarilumab added to non-biologic DMARDs in rheumatoid arthritis after TNF-alpha antagonist failure or intolerance
2011-003538-16Phase 3Completed
- Sponsor
- Sanofi
- Start
- Nov 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Sarilumab + non-biologic DMARD with Placebo + non-biologic DMARD (2 arms). Primary endpoint: ACR20 response. Started Nov 2012; status: completed.
02
Drugs
sarilumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2011-003538-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003538-16.